Loading
Loading
Research Overview
PTH/PTHrP receptor agonists that promote osteoblast activity over osteoclast activity, increasing bone mineral density; teriparatide is a PTH(1-34) fragment; abaloparatide is a PTHrP analogue with greater selectivity for the RG conformation reducing hypercalcaemia risk.
Teriparatide is a recombinant peptide comprising the first 34 amino acids of parathyroid hormone (PTH 1-34), the biologically active fragment of the full 84-amino acid PTH molecule. It acts as a PTH1R agonist with a well-characterised receptor engagement profile studied extensively in preclinical bone biology models. Abaloparatide is a synthetic analogue of PTHrP (PTH-related protein) 1-34, sharing the same receptor target but with a distinct binding mode that has been characterised preclinically for differential effects on PTH1R signalling conformations.
Preclinical bone biology research has used both compounds to study the mechanisms by which intermittent PTH1R activation promotes bone formation, distinguishing anabolic (bone-building) effects from catabolic bone resorption effects seen with continuous PTH1R stimulation. Animal model skeletal studies have used micro-CT, histomorphometry, and bone biomechanical testing to characterise changes in trabecular and cortical bone architecture under both compound treatment conditions.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, abaloparatide and teriparatide (pth receptor agonists) bone biology has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Abaloparatide and Teriparatide (PTH Receptor Agonists) Bone Biology research is most relevant to protocols examining:
Osteoporosis treatment and bone mineral density research
Osteoblast/osteoclast balance and anabolic bone biology studies
Fracture risk reduction investigations
Researchers comparing PTH vs PTHrP receptor selectivity profiles
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: Teriparatide: ~1 hour; Abaloparatide: ~1.7 hours). Review data, confirm baseline recovery before any repeat protocol.
PTH/PTHrP receptor agonists that promote osteoblast activity over osteoclast activity, increasing bone mineral density; teriparatide is a PTH(1-34) fragment; abaloparatide is a PTHrP analogue with greater selectivity for the RG conformation reducing hypercalcaemia risk.
| Parameter | Value |
|---|---|
| Dose range | Teriparatide: 20 mcg/day |
| Alt. dose 2 | Abaloparatide: 80 mcg/day |
| Schedule | Daily |
| Route | Subcutaneous |
| Half-life | Teriparatide: ~1 hour; Abaloparatide: ~1.7 hours |
limit treatment to 24 months)
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.